Infinium Pharmachem Limited (NSE:INFINIUM)
227.75
+7.75 (3.52%)
Aug 21, 2026, 3:23 PM IST
Infinium Pharmachem Revenue
In the fiscal year ending March 31, 2026, Infinium Pharmachem had annual revenue of 1.90B INR with 21.79% growth. Infinium Pharmachem had revenue of 1.06B in the half year ending March 31, 2026, with 42.37% growth.
Revenue
1.90B
Revenue Growth
+21.79%
P/S Ratio
1.87
Revenue / Employee
13.17M
Employees
144
Market Cap
3.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.90B | 339.22M | 21.79% |
| Mar 31, 2025 | 1.56B | 200.50M | 14.78% |
| Mar 31, 2024 | 1.36B | 214.34M | 18.76% |
| Mar 31, 2023 | 1.14B | 151.06M | 15.24% |
| Mar 31, 2022 | 991.19M | 443.60M | 81.01% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Remus Pharmaceuticals | 8.54B |
| Accent Microcell | 3.50B |
| Zenith Drugs | 1.71B |
| Quest Laboratories | 1.26B |
| Sotac Pharmaceuticals | 1.02B |
| Sunrest Lifescience | 708.33M |
| Vilin Bio Med | 422.63M |
| Medicamen Organics | 226.30M |